Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS >=550%, treatment-naive NSCLC

Satouchi, M; Hotta, K; Nosaki, K; Takahashi, T; Nakagawa, K; Aoe, K; Noguchi, K; Shimamoto, T; Rangwala, R; Brahmer, J

ANNALS OF ONCOLOGY, 2017; 28 ( ): 73

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索